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Background: The etiology of schizophrenia is extensively debated, and multiple factors 
have been contended to be involved. A panoramic view of the contributing factors 
in a genome-wide study can be an effective strategy to provide a comprehensive 
understanding of its causality.
Materials and Methods: GSE53987 dataset downloaded from GEO-database, which 
comprised mRNA expression data of post-mortem brain tissue across three regions 
from control (C) and age-matched subjects (T) of schizophrenia (N = Hippocampus [HIP]: 
C-15, T-18, Prefrontal cortex [PFC]: C-15, T-19, Associative striatum [STR]: C-18, T-18). 
Bio-conductor—affy—package used to compute mRNA expression, and further t-test 
applied to investigate differential gene expression. The analysis of the derived genes 
performed using the PANTHER Classification System and NCBI database. Further, a 
protein interactome analysis of the derived gene set was performed using STRING v10 
database (https://string-db.org/).
Results: A set of 40 genes showed significantly altered (p < 0.01) expression across all 
three brain regions. The analyses unraveled genes implicated in biological processes and 
events, and molecular pathways relating basic neuronal functions.
Conclusions: The aberrant expression of genes maintaining basic cell machinery explains 
compromised neuronal processing in SCZ.
Keywords: genome-wide expression study, genetic signature, hippocampus, associative striatum, prefrontal cortex
INTRODUCTION 
The etiology of schizophrenia (SCZ) is extensively debated (1, 2). Uncertainty of the etiology has 
greatly impeded the treatment of the disease, and neither of the therapeutic approaches (1) is 
proving much helpful in halting its progression.
Many candidate genes have been reported (3) for SCZ but none of them got validated in 
population-based studies for persistent association (4, 5). A disease signature derived from 
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genome-wide expression patterns in affected brain regions was 
highly desirable that would help to reach the diagnosis and 
developing optimal therapeutic approaches for SCZ.
SCZ gives a life time risk of ~1% and shows high heritability 
(~69–81%) (6–8). The SCZ heritability is derived from CNVs, 
SNPs, de novo mutations, and structural modifications at gene 
promoter regions without involving gene sequences as have 
been revealed in the genome-wide studies (9). Expression 
derangement of the genes also evidenced to arise of the gene- 
environment interactions during fetal development and in the 
lifetime of the individuals (10, 11).
SCZ has been noted to cause significant architectural changes 
in many brain regions, the hippocampus, prefrontal cortex, and 
basal nuclei (more specifically associative or dorsal striatum) 
have been chief among them (12–14). Neuronal gene expressions 
in the affected brain regions are known to alter in SCZ (15, 16). 
A comprehensive study of the gene expression dynamics in SCZ 
patients, which is shared by all three brain regions (hippocampus, 
prefrontal cortex, and associative striatum) may plausibly give a 
glimpse of the disease etiology.
How the neural architectural changes are instructed by the 
changes in the neural genes has also been shown by some recent 
studies. Piskorowski et al. (17) have shown in the mouse model 
that deletion of 22q11 locus may involve the genes making 
synaptic proteins and that may produce SCZ like symptoms (17). 
Fromer and colleagues (18) have identified over 100 of genetic 
loci harboring SCZ associated variants which together involve 
scores of genes, and altering the expression or knock down of 
some of such genes in animal or human stem cell models has 
shown to compromise neural functions effectively (18). Plausibly, 
the dysregulation of the neuronal genes, especially which are 
involved in maintaining basic cell architecture and machinery, 
may compromise the information processing in neurons in 
affected brain regions in SCZ (19, 20).
In this study, we hypothesized that the contributory factors 
involved in the etiogenesis of SCZ may get reflected in the altered 
expression of neuronal genes; hence an ontological analysis of 
these genes from the affected brain regions may unravel the 
components of the complex etiology of SCZ.
MATERIALS AND METhODS
Data Resources
The mRNA expression data were retrieved from the GEO 
(Genome Expression Omnibus, GSE53987) (http://www.ncbi.
nlm.nih.gov/geo/), a public repository for high-throughput 
microarray. The RNA was originally isolated from post-mortem 
brain tissue across three specific regions (hippocampus [HIP], 
prefrontal cortex [PFC]: Brodmann Area 46 [dorsolateral part 
of PFC], and Associative [or dorsal] striatum [STR]) of control 
(N = 18 [HIP], 19 [PFC], 18[STR]) and age-matched subjects 
with schizophrenia (N = 15 [HIP], 15 [PFC], 18 [STR]). For 
the original data, designated tissue samples were acquired from 
the curated collection of brain samples from the University 
of Pittsburgh which was permitted by the institute ethics 
committee (21, 22). Equal numbers of male and female (except 
for odd number samples) diagnosed SCZ cases and controls of 
adult age were chosen for this purpose (Table S1). The controls 
were matched for the age and sex with cases, and were free of 
any neurological or psychiatric illness during their life course. 
Tissue was collected from same hemisphere of the brain using 
same anatomical landmarks in all individuals. The post-mortem 
interval (PMI) and pH of the brain tissue, storage timing (at 
−80 degree Celsius), and RNA integrity number (RIN) (to 
confirm quality of processed RNA) for the test and controls were 
maintained to the set standard as were declared in the published 
records related to the original data source (21, 22). Also, history 
of taking tobacco products, centrally acting drugs, and any other 
medications and manner of death for the tests as well control 
samples were noted from the records (Table S1) (21, 22).
Data Retrieval and Analysis
The RNA was isolated from HIP, PFC (Brodmann Area 46), 
and associative STR and hybridized to U133_Plus2 Affymetrix 
chips for m-RNA expression study (21, 22). Expression analysis 
of mRNA was done by using "affy" package (http://www.
bioconductor.org/packages/release/bioc/html/affy.html), which 
was deposited at Bioconductor and developed in R statistical 
software program and scripting language. It used three steps to 
calculate the expression intensities: (i) background correction; 
(ii) normalization (data were normalized by RMA, subjected 
to pair wise comparison followed by Benjamini and Hochberg 
False Discovery rate correction [FDR]), and (iii) expression 
calculation. After calculation of mRNA expression intensity, a 
simple unpaired two tailed t-test (significance set at p ≤ 0.01) 
was applied to the data to filter out the set of genes expressed 
significantly in all three brain regions.
To categorize the derived significantly altered genes on the 
basis of their involvement in molecular functions, molecular 
pathways, and biological events, PANTHER (Protein ANalysis 
THrough Evolutionary Relationships) Classification System 
(http://www.pantherdb.org/) and NCBI gene database (http://
www.ncbi.nlm.nih.gov/gene/) were exploited. To construct a 
protein interactome network of the derived gene set STRING 
v10 database was used (https://string-db.org/). The pathway 
enrichment analysis results were extracted using Reactome 
Pathways of the STRING utility.
RESULTS
A set of 40 genes (protein coding-38; RNA-gene-2) was identified 
showing statistically significant (p ≤ 0.01) altered mRNA 
expression in schizophrenic patients in the all three brain regions 
studied (Table 1). Interestingly, it was observed that most of the 
genes were down-regulated in all three brain regions (32/40). 
Also, the same genes in all three brain regions have shown the 
similar direction of expression changes.
These genes were classified into six categories on the basis of 
their molecular functions (Figure 1). Further, the genes were 
Abbreviations: SCZ, Schizophrenia; HIP, Hippocampus; STR, Associative 
Striatum; PFC, Prefrontal Cortex.
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classified into fourteen categories on the basis of involvement 
in biological processes and events (Table 2). However, some 
genes belong to more than one category. The protein interactome 
network analysis of the gene-set revealed weak to strong 
interaction between only limited genes (Figure S1). Two cluster 
hubs were identified where more than two genes were observed 
to be interacting with each other. The salient genes which 
showed cross-talk in the interactome were ATP5D, UQCRC1 and 
ANAPC5, PSMC3 which are mainly involved in the basic cellular 
functions like energy production mechanisms and cellular 
growth, cell cycle regulation, and enzyme activity (Table 2).
Furthermore, in pathway linkage analysis, the gene set was 
found to link with 36 molecular pathways (Figure 2) that broadly 
could be placed in seven categories based on their commonality 
(Table S2).
DISCUSSION
The structural and functional brain abnormalities have been 
repeatedly reported in patients with SCZ (23). The brain regions 
chosen for this study (hippocampus, prefrontal cortex, and 
TABLE 1 | Genome wide m-RNA expression (statistical significance set at p ≤ 0.01) in three brain regions of schizophrenic patients and healthy controls (data 
represented as mean).
hippocampus prefrontal cortex Associative striatum
Gene symbol Control SCZ fold 
change
p-value Control SCZ fold 
change
p-value Control SCZ fold 
change
p-value
(n = 15) (n = 18) (Control/
SCZ)
(n=15) (n = 19) (Control/
SCZ)
(n = 18) (n = 18) (Control/
SCZ)
MSANTD3 8.33 8.03 0.96 0.001 8.71 8.71 0.98 0.003 8.15 8.03 0.99 0.006
CXADR 5.52 5 0.9 0.001 5.46 5.46 0.93 0.003 5.83 5.44 0.93 0.004
ZNF385B 6.27 5.47 0.87 <0.001 8.3 8.3 0.97 0.005 8.44 7.61 0.9 0.008
SAFB2 7.12 7.46 1.05 0.005 6.88 6.88 1.04 0.002 7.49 7.74 1.03 0.006
FBXO9 
1559094_at
9.49 8.71 0.91 <0.001 10.19 10.19 0.95 0.002 8.78 8.28 0.94 0.002
FBXO9 
1559096_x_at
10.68 10.07 0.94 <0.001 11.25 11.25 0.97 0.004 10.27 9.95 0.97 0.003
MCL1 9.74 10.23 1.05 0.002 9.76 9.76 1.03 0.002 9.83 10.25 1.04 0.002
PITPNA 10.74 10.39 0.96 <0.001 11.18 11.18 0.99 0.006 10.31 10.16 0.99 0.008
PSMC3 9.64 9.17 0.95 <0.001 9.92 9.92 0.98 0.008 10.15 9.8 0.97 0.008
IFITM2 9.77 10.46 1.07 0.001 9.29 9.29 1.06 0.003 10.04 10.47 1.04 0.008
ICMT 8.09 7.93 0.98 0.008 8.22 8.22 0.97 0.001 8.83 8.43 0.95 <0.001
UQCRC1 10.7 10.29 0.96 <0.001 11.06 11.06 0.99 0.003 10.69 10.46 0.98 0.008
ASNA1 9.3 8.99 0.96 <0.001 9.42 9.42 0.99 0.006 9.19 8.99 0.98 0.008
TIAL1 7.97 7.7 0.96 <0.001 7.94 7.94 0.98 0.003 7.89 7.67 0.97 0.003
GTF2H1 7.59 7.02 0.92 <0.001 8.04 8.04 0.97 0.002 7.38 6.96 0.94 0.003
ANPEP 9.22 10.26 1.11 < 0.001 8.81 8.81 1.09 0.004 9.36 10.11 1.08 0.005
SOX9 9.39 9.7 1.03 0.008 9.07 9.07 1.05 0.001 9.41 9.7 1.03 0.002
CHSY1 8.18 8.64 1.05 0.001 8.29 8.29 1.04 0.002 8.2 8.49 1.03 0.007
BCL6 9.78 10.48 1.07 <0.001 10.18 10.18 1.03 0.002 9.52 10 1.05 0.009
PDCD6 10.11 9.65 0.95 <0.001 10.29 10.29 0.98 0.004 10.01 9.73 0.97 0.005
ERCC1 9.13 8.84 0.97 <0.001 9.09 9.09 0.98 0.008 8.85 8.65 0.98 <0.001
MYO5A 8.7 8.3 0.95 0.003 9.24 9.24 0.96 0.004 7.69 7.35 0.95 0.002
KCNK1 10.73 10.4 0.97 0.003 10.9 10.9 0.98 0.003 10.08 9.78 0.97 0.008
GNAO1 10.58 10.23 0.96 0.006 10.61 10.61 0.97 0.001 10.37 10.03 0.97 0.005
HAPLN1 5.84 5.14 0.88 0.002 5.88 5.88 0.94 0.002 4.77 4.49 0.94 0.007
PPM1E 9.12. 8.26 0.9 0.007 7.62 7.62 0.96 0.008 6.37 6.08 0.95 0.001
KAT5. 8.46 8.29 0.97 0.001 8.7 8.7 0.99 0.008 8.68 8.56 0.99 0.008
MAPK9 8.13 7.5 0.92 <0.001 8.74 8.74 0.96 0.001 8.03 7.63 0.95 0.003
SPAG7 9.9 9.65 0.97 <0.001 9.92 9.92 0.99 0.001 9.52 9.37 0.98 0.001
ANAPC5 11.02 10.84 0.98 <0.001 10.95 10.95 0.99 0.001 11.02 10.8 0.98 0.009
ATP5D 10.71 10.4 0.97 <0.001 10.76 10.76 0.98 0.005 10.66 10.46 0.98 0.008
UBE4B 7.76 7.5 0.96 0.006 8.03 8.03 0.98 0.01 7.71 7.45 0.97 0.004
SCRN3 8.12 7.65 0.94 0.001 8.18 8.18 0.98 0.008 7.64 7.27 0.95 0.002
SMIM7 9.13 8.77 0.96 0.001 9.35 9.35 0.98 0.005 9.38 9.05 0.96 0.002
PDK4 8.24 9.15 1.11 0.001 7.98 7.98 1.11 <0.001 8.6 9.27 1.07 0.003
RBM18 9.31 8.99 0.96 0.001 9.6 9.6 0.99 0.006 9.18 8.96 0.98 0.003
SAMD5 6.76 6.38 0.94 0.006 6.85 6.85 0.96 0.001 7.47 6.85 0.92 <0.001
CADPS 6.43 6.2 0.96 0.004 6.4 6.4 0.96 0.005 6.1 5.89 0.97 0.004
LOC100506538///
NDUFAF6
8.13 7.57 0.94 0.001 8.5 8.5 0.97 0.004 8.11 7.69 0.95 0.008
LOC100507534 6.38 5.28 0.83 0.002 6.29 6.29 0.88 < 0.001 4.42 4.19 0.95 0.007
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striatum) are known to be predominantly affected (12–14) and 
their dysfunctions (contributing to characteristic symptoms as 
altered cognition, loss of executive functions, and disorganized 
thought and behavior) are common in SCZ (24–26). Recent 
studies supported an altered gene expression in of these brain 
regions in SCZ (27, 28). A comprehensive study of the genome 
expression status in these brain regions was expected to unravel 
mysterious etiology of SCZ.
As the genes selected for the analysis were found significantly 
altered in all three studied brain regions, these expression 
changes may be reflecting the actual pathophysiological changes 
occurring in neuronal functions in SCZ. None of the genes 
revealed in this study had been reported earlier as a candidate 
gene for SCZ, hence the new set appealed for a fresh attention to 
understand the disease etiology.
Involvement of the Gene Set in 
Molecular functions
The functional analysis of the gene-set (Figure 1) elucidated 
the genes being involved in regulation of basic machinery and 
housekeeping functions of the neurons viz. receptor-ligand 
binding, catalysis, enzymatic regulation, nucleic acid binding 
transcription factor activity, structural molecule activity, and 
transport activities. It is well evident that dysregulation of 
these basic functions in neurons may manifest in compromised 
information processing in brain which has been a hallmark of 
the progressed SCZ (29). The molecular function analysis also 
showed hierarchy of the functions that may be compromised in 
SCZ (Figure 1) (the catalysis and receptor-ligand binding being 
most affected functions).
fIGURE 1 | Involvement of the gene set in molecular functions. (Catalysis (n = 17, p = 44.7%), binding (n = 13, p = 34.2%), and nucleic acid binding transcription 
factor activity (n = 5, p = 13.2%), transporter activity (n = 4, p = 10.50%), enzyme regulation (n = 3, p = 7.90%), and structural molecule activity (n = 2, p = 5.3%), 
n = number of genes, p = percentage. Source: Panther Classification System).
TABLE 2 | Involvement of the gene set in biological processes and events.
a Ubiquitination FBXO9, ANAPC5, UBE4, SMIM7
b Enzyme activity PPM1E, MAPK9, ATP5D, ICMT, 
PDK4, PSMC3
c Energy production mechanisms UQCRC1, ASNA1, ATP5D, PDK4
d Cell growth MAPK9, ANAPC5, CHSY1
e programmed cell death IFITM2a, TIAL1a, PDCD6a, MCL-1b
f Cytoplasmic vesicular transport 
and exocytosis
MYO5A, PITPNA, ASNA1, 
CADPS, SCRN3
g Dynamic regulation of 
cytoskeleton
MYO5A
h Ion channel homeostasis KCNK1, PDCD6
i Lipid binding and synthesis PITPNA, CAPDS
j DNA repair ERCC1, KAT5
k m-RNA transcription MSANTD3, GTF2H1, GNAO1, 
MAPK9
l post transcriptional gene 
modifications
KAT5
m protein translation TIAL1
n Cell cycle regulation ANAPC5, MAPK9
NCBI gene database (http://www.ncbi.nlm.nih.gov/gene/). a = Pro-apoptotic, b = 
Anti-apoptotic.
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Involvement of the Gene Set in Biological 
processes and Events
The comprehensive influence of the dysregulation of these genes 
in the pathogenesis of SCZ gets further clarified in the analysis 
for the involvement in the biological processes and cellular events 
(Table 2). The implication of genes involved in ubiquitination 
(Table 2-a), enzyme activity (Table 2-b), and energy production 
mechanisms (Table 2-c) may point towards a failure of the basic 
functions in neurons; as ubiquitination is known to regulate the 
diverse spectrum of cellular functions (30) and the same should 
be true for the genes encoding enzymes, especially those necessary 
for mitochondrial functions (ATP5D, PDK4) (31), regulating 
specific signaling pathways (MAPK9) (32) and involved in 
phosphorylation (ATP5D, PDK4) or dephosphorylation (PPM1E) 
(25, 33). The dysregulation of genes involved in energy production 
(Table 2-c) supports prevailed view in the literature that energy 
production mechanisms get compromised in SCZ (34, 35).
Furthermore, down-regulation of genes which function as 
regulator of the cell growth mechanisms (Table 2-d) provides 
a possible explanation for reduced neuronal cell sizes, synaptic 
connection and brain volume in specific brain regions noted 
in schizophrenia (36) The significant upregulation of genes 
involved in the programmed death (Table 2-e) may indicate 
pro-apoptotic mechanisms prevailing in particular brain regions 
in schizophrenia which gets support from some earlier studies 
(37, 38). Though, the pro-apoptotic mechanisms may not be a 
generalized feature in SCZ, as we also noted contrary evidence 
that an anti-apoptotic gene MCL-1 was found significantly 
upregulated in all three brain regions. [Contrastingly, sMCL-1 
regulates cell cycle negatively hence limiting the mitosis (39)].
Also, the significantly altered expression of the genes involved 
in cytoplasmic vesicular transport and exocytosis (Table 
2-f), dynamic regulation of actin and tubulin cytoskeleton 
(Table 2-g), and ion channel homeostasis (Table 2-h), lipid-
binding (PITPNA) and synthesis (CADPS) (Table 2-i) hint of 
compromised neuronal information processing in SCZ.
Indications From Interactome Analysis of Gene Set
The protein-protein interaction analysis of the gene set revealed 
cross-talk between ATP5D (Table 2-b, c), UQCRC1 (Table 2-c), 
fIGURE 2 | Involvement of the gene set in molecular pathways (Out of 40 genes only 38 are protein coding for which pathway involvements are known and has 
been presented here).
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and ANAPC5 (Table 2-d, n), PSMC3 (Table 2-b) (Figure S1) 
which further strengthen the view that basic (neuronal) cell 
functionary of the selective brain regions could be the focus of 
the pathogenesis in SCZ. We detected two central hubs showing 
strong interaction between the genes involved in ubiquitination 
(ANAPC5), enzyme activity (ATP5D, PSMC3), energy production 
mechanism or mitochondrial functions (ATP5D), and cell cycle 
regulation (ANAPC5) (Figure S1). Existing literature suggests 
that a dysregulation of the noted biological processes and events 
could be at the core of SCZ pathogenesis (40–42).
Involvement of the Gene Set in Molecular 
pathways
In pathway linkage analysis (Figure 2, Table S2), the category 
involving largest number of molecular pathways has been that 
of neurotransmitters/modulators and neurohormones (Table 
S2-a) which fits with clinical manifestations of the disease and 
also gets support from existing theories that the etiology of 
SCZ majorly may be based on dysregulation of this category of 
molecules (43).
Various neurotransmitters-based hypotheses have been 
proposed for the etiology of SCZ (44) but none of them are 
primarily explaining causality of the diseases. The result of 
this study (Figure 2, Table S2) indicates that disease etiology 
is not implicating any single transmitter but many of them 
together (45).
The linkage of the immune cell/chemokine mediated pathways 
(Table S2-b) is strongly supported by literature (46, 47). An 
immunogenic basis of SCZ etiogenesis had also been brought 
forward (48) although counter to this hypothesis has also been 
placed which limits the role of immune function related genes as 
a solo or major factor in SCZ etiology (49).
In a recent study (21), Lanz et al. who performed pathway 
analysis of transcriptional profiles in post-mortem samples of 
HPC, PFC, and associative STR from SCZ patients (using the 
same dataset which we used in our study) found enrichment of 
the transcripts involved in inflammatory pathways. Enrichment 
of the inflammatory pathways was also reported by Scarr et al., 
who examined transcriptional profiles from PFC of post-mortem 
SCZ patients (50).
Also, the involvement of growth, differentiation, and 
survival of neurons in the specific brain regions (Table S2-c) 
(51, 52) (also discussed in subsection Involvement of the Gene 
Set in Biological Processes and Events) and pathways related to 
apoptosis (Table S2-d) (37, 38), and related to protein synthesis 
(Table S2-e) and degradation (Table S2-f) (53) has been well 
documented in the literature (also discussed in subsection 
Involvement of the Gene Set in Biological Processes and Events). 
The linkage of FGF signaling pathway (Table S2-c) under 
neuronal growth, differentiation, and survival to SCZ etiology 
has been corroborated by a freshly published study by Narla 
et al. (54) who regarded it as a central pathway commanding 
all other pathways in developing brain strengthening the view 
that SCZ has a neurodevelopmental etiology (54). In contrast, 
the linking of the pathways involved in the pathogenesis 
of major neurodegenerative diseases (Table S2-g) such as 
Alzheimer, Parkinson, and Huntington’s disease indicates 
neurodegenerative nature of SCZ.
Non-protein-Coding Genes: Unknown 
functions
The neuronal functions associated with two non-coding genes 
(LOC100507534, LOC100507534) couldn’t be ascertained from 
the literature but it’s interesting to find significant alterations 
of these long non-coding RNAs in SCZ which have never been 
reported before. There are now strong indications that non-
coding genes are implicated in SCZ pathology (55).
LIMITATIONS Of ThIS STUDY AND 
fURThER RESEARCh
The confounding factors such as the history of addiction 
(including alcohol intake) or substance abuse, and drug 
intake might have some impact on the transcriptional data. A 
separate analysis of the impacts of these confounding factors 
(especially that for addiction and substance abuse) might have 
given additional insights to this study. Additionally, a separate 
analysis of the impact of the sex of the subject on the resultant 
data could have provided important insights regarding sex-
specific pathogenesis in SCZ. We couldn’t analyze these factors 
separately either due to the lack of related data or limitation of 
the sample sizes.
Though, we have included only those genes for further 
analysis which showed significant change of expression in all 
three studied brain regions, the fold changes for the genes are not 
very large to derive strong conclusions. Validation of the analyzed 
data with more than one gene expression analysis methods could 
have been necessary, and could have further augmented the value 
of this study. The genes which were significantly altered in only 
one or two and not in all three brain regions selected for the 
study have not been included in analysis to keep the study design 
robust, but they might carry some value in disease etiology. A 
neural circuit specific analysis of the changes in gene expressions 
targeted to the individual neurocognitive domains may further 
enhance the etiological clarity on SCZ.
Testing validity of the proposed gene set as a SCZ genetic 
signature is a remaining task which needs to be studied further. 
A rigorous search of the SCZ gene expression databases linked to 
the noted brain regions will make this clear. Also, looking for the 
similar gene expression changes in the blood cells and/or skin 
fibroblasts (though there is limited evidence for this in literature 
for now) (56, 57), will be greatly informative for assigning any 
prognostic (or diagnostic) value to the gene set.
CONCLUSIONS
Molecular characterization of the gene set unraveled in this 
study gives a glimpse of the complex etiogenetic mechanisms 
involved in SCZ, an understanding of which may have useful 
implications in the therapeutic management of the disease. Most 
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of the genes in the set participate in the maintenance of basic cell 
machinery which explains why their aberrant expression may 
cause compromised neuronal processing in SCZ.
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